Remimazolam is used for sedation during medical procedures and for inducing anesthesia before surgery, helping patients stay calm and comfortable during these medical interventions.[2] Anerem is currently approved and in use across 40 indications[4].[1]
Anerem is one of 491 small molecule programs targeting Sedation. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
137 competitors in Atrial Fibrillation
Anerem
Calquence
Rituxan
Coumadin
Brukinsa
Imbruvica
Versed
Ondexxya
Statin
Low-Molecular-Weight Heparin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 6, 2020
BYFAVO
NDA NDA212295
Sources
Details